Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Pfizer Maternal C-19 Vaccine Trial has launched at Oxford University Hospitals NHS Foundation Trust for women between 24-34 weeks pregnant. The Nuffield Department of Women’s & Reproductive Health’s team of doctors, research midwives and nurses are delivering this critical trial to evaluate the safety, tolerability, and immunogenicity of the Pfizer vaccine in pregnant women.


For the first time in the UK, a COVID-19 vaccine study for pregnant women has launched. It seeks to learn about the safety and effectiveness of the Pfizer Maternal C-19 Vaccine for all expectant mothers and their babies.

A local COVID-19 research study will compare an investigational (study) vaccine against a placebo to see if the study vaccine can prevent COVID-19. 

This national study is led by the National Institute for Health Research. Managing the study for the John Radcliffe Hospital in Oxford, is the OSPREA Team of research midwives and nurses who are part of the Nuffield Department of Women's & Reproductive Health. 

Prof Manu Vatish, Lead for the NIHR Clinical Research Network in the Thames Valley commented:

"We are delighted to be taking part in this important study which is crucial to help us understand both the safety and immunogenicity of the Pfizer-BioNTech vaccine for pregnant women and their children. We know that approved COVID-19 vaccines are safe for pregnant women as per JCVI guidance, but this will add valuable information to our knowledge of how these vaccines work".

The team are looking for women who are between 24-34 weeks pregnant to participate in the trial. Those enrolled will receive either two doses of the vaccine, or a placebo, given 21 days apart. One month after giving birth they will then be "unblinded" - and those who didn't get the vaccine will be given it.



If you’re interested in learning more about this clinical trial for you and your baby, please or call 01865 221107.

You can download a poster with further information about this clinical trial here.


Our Research Groups